Although small- and medium-sized biotechs are absent from the NIH 's new Accelerating Medicines Partnership with industry and not-for-profit organizations, consortium leaders expect that making results publicly available on their search for new targets and...

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Uridine phosphorylase 1 (UPP1) Cell culture studies identified UPP1 inhibitors that could be useful for improving the efficacy of 5-fluorouracil...

When Millennium Pharmaceuticals Inc. began working on the first proteasome inhibitor to reach the market, Velcade bortezomib, one of the potential issues was that the presence of proteasomes in all cells and the proteasome's broad...